Citigroup
RVLP

Citigroup’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Citigroup’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,356
Closed -$18K – 6060
2022
Q3 		$18K Buy
+8,356
New +$16.2K ﹤0.01% 4788
2021
Q4 		– Sell
-3,526
Closed -$10K – 6156
2021
Q3 		$10K Sell
3,526
-1,607
-31% -$5.4K ﹤0.01% 5478
2021
Q2 		$15K Buy
5,133
+2,019
+65% +$6.18K ﹤0.01% 5484
2021
Q1 		$10K Sell
3,114
-1,525
-33% -$6.27K ﹤0.01% 5664
2020
Q4 		$19K Buy
4,639
+267
+6% +$1.54K ﹤0.01% 6701
2020
Q3 		$24K Sell
4,372
-829
-16% -$4.78K ﹤0.01% 6071
2020
Q2 		$35K Sell
5,201
-1,027
-16% -$5.03K ﹤0.01% 6234
2020
Q1 		$20K Buy
6,228
+630
+11% +$3.35K ﹤0.01% 6706
2019
Q4 		$39K Buy
5,598
+4,298
+331% +$22.9K ﹤0.01% 6518
2019
Q3 		$5K Sell
1,300
-741
-36% -$2.51K ﹤0.01% 7359
2019
Q2 		$8K Sell
2,041
-933
-31% -$3.1K ﹤0.01% 7374
2019
Q1 		$11K Buy
2,974
+2,383
+403% +$17.5K ﹤0.01% 7234
2018
Q4 		$5K Buy
+591
New +$4.73K ﹤0.01% 7367

Other funds holding RVLP

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
RA
Rovida Advisors Fort Lauderdale, Florida $116M AUM 12.52% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup's RVLP Position: Q4 2022 in Review

Citigroup sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2022, closing a stake of 8,356 shares — an estimated $18K sold.

Citigroup first reported a position in RVLP in Q4 2018 and held it in 13 quarters. The position peaked at $39K in Q4 2019. 36 funds tracked by Wall St. Rank hold RVLP as of Q4 2022.

  • Citigroup reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2022 after selling out during the quarter.
  • Citigroup sold 8,356 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2022, an estimated $18K.
  • Citigroup first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2018 and held it in 13 quarters.
  • Citigroup's RVL Pharmaceuticals plc Ordinary Shares position peaked at $39K in Q4 2019.
  • 36 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2022.

Based on Citigroup's 13F filing for Q4 2022, filed 9 Feb 2023.